when will retatrutide be fda approved Retatrutide, an experimental weight-loss drug, has not been by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide's TRIUMPH-1 result explains why

TABLE 6 Pharmacokinetic parameters of BPC157 in dogs following repeated intramuscular administration at a dose of 30 g/kg for seven consecutive days (mean SD, n = 6)

The SELECT trial specifically demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease, regardless of diabetes status

Clinical trials evaluating these medications have not identified thirst as a frequent or characteristic side effect directly attributable to the pharmacologic action of GLP-1 receptor activation

Research summarized by Mayo Clinic suggests that approximately 25% to 40% of GLP-1 weight loss may come from lean mass, which includes more than muscle